Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017
Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017
This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumb), a candidate for biosimilar conversion in the near future.
RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.
The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series deliversNO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companiesat low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumb), a candidate for biosimilar conversion in the near future.
RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.
The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series deliversNO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companiesat low prices. The information is provided in a tabular format and fully referenced.
RSV ANTIBODIES:
Palivizumab Biosuperiors
Palivizumab Biosimilars
RSV ANTIVIRALS:
Small Molecule Therapeuticss
Other RSV Therapeutics
RSV VACCINES:
Live-Attenuated & Whole-Inactivated RSV Vaccines
Virus-Like Particle (VLP) RSV Vaccines
Subunit RSV Vaccines
DNA-/RNA-Based RSV Vaccines
Palivizumab Biosuperiors
Palivizumab Biosimilars
RSV ANTIVIRALS:
Small Molecule Therapeuticss
Other RSV Therapeutics
RSV VACCINES:
Live-Attenuated & Whole-Inactivated RSV Vaccines
Virus-Like Particle (VLP) RSV Vaccines
Subunit RSV Vaccines
DNA-/RNA-Based RSV Vaccines
